Establishment Labs (NASDAQ:ESTA) Shares Gap Down – What’s Next?

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $70.99, but opened at $64.42. Establishment Labs shares last traded at $68.6070, with a volume of 269,607 shares traded.

Analyst Ratings Changes

Several equities research analysts recently commented on ESTA shares. Stephens lifted their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Needham & Company LLC lifted their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Wall Street Zen downgraded shares of Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research report on Wednesday. Finally, Canaccord Genuity Group boosted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $87.14.

Establishment Labs Stock Down 0.4%

The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -48.17 and a beta of 1.12. The company has a current ratio of 3.04, a quick ratio of 2.00 and a debt-to-equity ratio of 10.51. The stock’s 50-day moving average price is $65.27 and its 200-day moving average price is $66.59.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative return on equity of 202.78% and a negative net margin of 19.05%.The firm’s revenue for the quarter was up 44.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.70) EPS. On average, sell-side analysts expect that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current year.

Insider Activity

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the transaction, the director owned 927,504 shares in the company, valued at $69,952,351.68. The trade was a 10.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 330,000 shares of company stock valued at $22,854,538. 9.99% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. KBC Group NV acquired a new position in shares of Establishment Labs during the 1st quarter valued at $28,000. Kestra Advisory Services LLC acquired a new position in shares of Establishment Labs during the 4th quarter valued at $47,000. Quarry LP acquired a new position in shares of Establishment Labs during the 3rd quarter valued at $34,000. State of Wyoming acquired a new position in shares of Establishment Labs during the 3rd quarter valued at $71,000. Finally, MV Capital Management Inc. acquired a new position in shares of Establishment Labs during the 4th quarter valued at $146,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.